Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans”,”expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Food and Drug Administration at this time. MGuard ™ EPS and CGuard ™ EPS are CE Marked and are not approved for sale in the U.S. MGuard Prime™ is a Cobalt Chromium stent wrapped in MicroNet™. While offering superior performance relative to standard stents in STEMI patients, MGuard Prime™ requires no change in current physician practice – an important factor in time-critical settings. MGuard Prime ™ EPS, integrated with MicroNet™, is designed to trap and seal thrombus and ruptured plaque, preventing distal embolization. MicroNet™ is a bio-stable mesh woven from a single strand of 20 micron Polyethylene Terephthalate. The CGuard™ EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels. The proprietary CGuard ™ Embolic Prevention System (EPS) uses the same MicroNet™ ™ technology featured on the MGuard ™ and MGuard Prime ™ coronary Embolic Protection Systems. InspireMD’s common stock is quoted on the NYSE MKT under the ticker symbol NSPR. InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard TM), neurovascular, and peripheral artery procedures. InspireMD (seeks to utilize its proprietary MGuard™ with MicroNet™ TM technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. Foreign patent rights include 13 issued patents focused in Israel, Canada, and China, and 16 pending patent applications. To-date, the Company’s patent rights in the United States include 4 issued patents and 10 pending applications. The issuance of these two patents provides further support for these pending therapies and applications. InspireMD continues to maintain a focus on its intellectual property portfolio, expanding coverage for its proprietary MicroNet™ TM technology, CGuard TM Embolic Prevention System for the treatment of carotid artery disease, and MGuard TM for coronary applications, in addition to several pending applications directed to its neurovascular and peripheral vascular platforms. The Optimized Drug Stent Assembly patent covers a stent assembly with the Company’s proprietary MicroNet™ TM technology that elutes a drug. The In Vivo Filter Assembly patent covers an assembly for filtering debris flow in a blood vessel. 9,132,003 entitled “Optimized Drug Eluting Stent Assembly.” 9,132,261 entitled “In Vivo Filter Assembly” and U.S. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that the United States Patent & Trademark Office has issued two new patents to the Company on September 15 th, U.S. InspireMD Announces the Issuance of Two United States PatentsĬontinued Focus on Intellectual Property Results in Continued Portfolio ExpansionīOSTON, MA – Septem– InspireMD, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |